Audit: QRS - Glucoraphanin for Health & Longevity
Audit conducted on 24/08/2026 11:03 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol doses (ER l.342–344, l.352), time-to-effect values (ER l.399), benefit and risk tiers (ER l.155–223, l.247–279), contraindications (ER l.313–318), interactions (ER l.297–311), biomarker table (ER l.429–439), cadence (ER l.427), qualitative markers (ER l.443–447). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No circadian data exist” (action_3_sub) and “a marker, not a disease outcome” (time_3_sub) carry the ER’s own hedges from l.352 and l.193. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain avoid-level force; the sprout-specific scope qualifier is preserved so the over-65 item is not broadened beyond the ER (ER l.316). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All [stop_items] and [caution_items] originate in the ER Key Interactions & Contraindications section; no Benefit- or Risk-Modifying Factor content was migrated into the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, expert names or brand names (Avmacol, Prostaphane, Beneforté, SFX-01) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register matching the ER’s Conclusion and Protocol sections. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds throughout, with plain-language framing in At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as observed findings and reference ranges, not instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring cadence and gates are stated descriptively, mirroring the ER’s own wording. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending or advising verbs appear in the sheet’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to biomarker names carried verbatim from the ER’s monitoring table. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit, and risk item is a single short clause. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal functional ranges rather than conventional lab cutoffs are used throughout the Monitoring table. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Whole-food equivalents, enzyme pairing, and a nine-marker monitoring panel all presume effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Non-routine markers (apolipoprotein B, HOMA-IR, urinary sulforaphane metabolites) are retained. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance flags that benefit concentrates where baseline values started poor, matching the ER’s responder framing. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout; the plain-language phrasing in At-A-Glance is required by item 7.4 and mirrors the ER Conclusion (ER l.479). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Verified at QRS l.446, l.491, l.539, l.607, l.629, l.783, l.571, l.588, tier labels at l.543/549/554/561 and l.610/613/616/620, column headers at l.633–635. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 66 uniquely named spans present, covering header (4), at-a-glance (1), protocol actions (9), time-to-effect (9), benefits (4), gates (2), risks (4), markers (27), cadence (1), qualitative (5). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable template spans (website="evidence_review", website="full_review", website="audit") are intact and empty as shipped. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard supplemental dose”, “Whole-food equivalents”, “Best time of day” are verbatim from ER l.342, l.344, l.352; interaction labels are verbatim from ER l.299–311. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Benefit, risk, and marker labels reproduce the ER’s own headings and table row names. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s “⚠️ Conflicted” markers were correctly stripped from benefit and risk items. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every gate, benefit, and risk entry is condensed to a single clause and marker targets are trimmed (e.g., “< 70 with existing artery disease”); no content is carried onto a second sheet. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS l.2–14, immediately after the doctype at l.1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at l.3, closing “—” at l.13; the descriptive text at l.2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element repeats the values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | l.4 — er_filename: glucoraphanin_2026-0824-0725_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | l.5 — qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | l.6 — qrs_creation_date: 2026-0824-1050. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | l.7 — qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | l.8 — qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | l.9 — qrs_filename: glucoraphanin_2026-0824-0725_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS l.22 — “Glucoraphanin for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic (ER l.8). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS l.417 — “Glucoraphanin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS l.421 — “08/24/2026”, matching qrs_creation_date: 2026-0824-1050. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS l.425 — “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER l.475, l.477 and l.479 into conversion dependence, the two firmest outcomes, cognition, and the tolerability limit. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Inactive precursor → ER l.475; cholesterol and blood sugar falls concentrated in poor baselines → ER l.477; thinking speed in older adults → ER l.477; stomach upset and raw-sprout infection risk → ER l.479. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “artery-clogging cholesterol”, “blood sugar”, “thinking speed”, “a second compound” — no acronyms or clinical-register terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial identifiers of any kind. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Only the qualitative “modest” is used; no figures. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All four items trace to “Populations who should avoid Glucoraphanin” at ER l.313–318. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four ER avoid-list entries are present at QRS l.574–583; none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four <li> elements inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The rationale clauses “no supplemental-dose safety data…” and “per standing food-safety guidance; extracts are not implicated” were dropped; only the scope-defining fragment was retained as a parenthetical per item 8.5. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(thyroid-stimulating hormone above 10 mIU/L), until corrected” and “(raw or home-sprouted sprouts only)” both preserved; “unless cleared by the treating oncologist” retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid-list bullets use no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify such populations (l.315–318) and the section is correctly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items trace to the interaction bullets at ER l.297–311. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Seven of the ER’s eight interaction bullets appear; “Cytotoxic chemotherapy” is correctly omitted because it already sits in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the [caution_items] span (QRS l.591–597). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is reduced to the ER’s bold label alone; the “Caution”/”Monitor” verdicts, mechanisms, and “— additive effect” clauses are all stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named drug lists preserved verbatim: “(berberine, chromium, alpha-lipoic acid)”, “(plant sterols, red yeast rice, soluble fibre)”, “(paracetamol)”, “(methimazole, propylthiouracil)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation; all parentheses already hold plain comma-separated lists. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies eight such entries and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets at l.342, l.344 and l.352. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, whole-food equivalent, and timing — the three bullets that are directly executable; the myrosinase-pairing point is folded into action_3_sub. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans populated (QRS l.450–486); values and subs match ER l.342, l.344, l.352. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Lipid/glucose/liver at 8–12 weeks, PSA from month 3, and detoxification markers at 24–72 hours — the three windows named in ER l.399. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High tier (LDL and glycemic control) → Medium tier (PSA) → Low tier (pollutant clearance), matching the ER’s benefit grading. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans populated (QRS l.497–532); subs draw on ER l.427, l.179 and l.193. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (l.399). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten items map one-to-one onto the ER benefit headings at l.157–223. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at QRS l.541, l.547, l.552, l.559. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; all Magnitude: lines and “⚠️ Conflicted” markers are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All five items map onto the ER risk headings at l.249–279. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at QRS l.609, l.612, l.615, l.618. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; the Magnitude: figures (16.7% vs 2.0% nausea, 3,900 illnesses) are absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; “⚠️ Conflicted” removed from “Thyroid effects”. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and “Why” text reproduce the ER biomarker table at l.429–439. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers present in ER order: LDL, apolipoprotein B, HbA1c, fasting glucose, fasting insulin with HOMA-IR, ALT, GGT, TSH with free thyroxine, urinary sulforaphane metabolites. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS l.773–777 condenses ER l.425–427: baseline, 12-week lipid/glucose/liver repeat, 3-month conditional thyroid recheck then annual, full set every 6–12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items reproduce the ER’s “Qualitative markers worth tracking” list at l.443–447. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present and in ER order (QRS l.786–811). |
Issues 24/08/2026 11:03
Pass rate 100.00%. No issues found.
Issues 24/08/2026 10:56
- 9.5 — Paracetamol synonym dropped: The Key Interactions item at line 595 reads “Acetaminophen and other drugs cleared by glutathione conjugation”, dropping the ER bullet’s parenthetical “(paracetamol)” that identifies the drug for readers outside the United States.
Fixes 24/08/2026 10:56
- 9.5 — Paracetamol synonym restored: Restored the ER’s parenthetical alternate name in the Key Interactions item, changing “Acetaminophen and other drugs cleared by glutathione conjugation” to “Acetaminophen (paracetamol) and other drugs cleared by glutathione conjugation”.